Download resume - Covenant University

CURRICULUM VITAE

A. GENERAL INFORMATION
1. Full Name: OWOLABI, Joshua Babatunde
2. Date and Place of Birth: 6th July, 1956; Fiditi, Oyo State
3. Marital Status: Married
4. Number of children and their ages: Three (3); 30, 28, 18 years
5. Permanent Contact Address: 1713 Nathan Lane, Libertyville, IL 60048, U.S.A.
6. E-mail: [email protected] , [email protected]
7. Nigerian Mobile Number: 0-815-563-6901
8. College: Science and Technology
9. School: Natural and Applied Sciences
10. Department: Biological Sciences
11. Position on First Appointment: Senior Lecturer (Enhanced)
12. Present Position and Salary (grade level and step): Senior Lecturer (Enhanced); CUSS N12 Step 6
13. Date of Present Position (Promotion / Re-grading): 9th February, 2012 (Reported 3rd September, 2012)
14. Appointment Confirmation: No
15. Date of Confirmation of Appointment: Not Applicable
B. EDUCATIONAL BACKGROUND
1. Educational Institutions Attended with Dates
a.) University of Ife, (now Obafemi Awolowo University), Ile-Ife (1975 – 1979)
b.) University of Ife, (now Obafemi Awolowo University), Ile-Ife (1981 – 1982)
c.) University of British Columbia, Vancouver, Canada (1982 - 1988)
d.) North Park University, Chicago, USA (2004 – 2006)
2. Academic and Professional Qualifications with Dates
a.) B.Sc. (2nd Class Upper Hon.) Microbiology (July 1979)
b.) M.Sc. Microbiology (Physiology) (July 1982)
c.) Ph.D. Microbiology (Molecular Genetics) (May 1988)
d.) Post-Graduate Certificate in Organizational Development (May 2006)
e.) Master’s in Business Administration (May 2006)
3. Other Relevant Qualifications / Selected Continuing Education & Professional Development
a.) Win/win Alliance Partnerships, Drugs Information Association, 2006
b.) Pharmaceutical and Biotechnology Portfolio Management, S.R.I, 2006
c.) Strategic IP Due Diligence: Assessing Risks & Opportunities, Licensing Executives Society, 2007
d.) Competitive Intelligence 101 & 201, Fuld & Company, 2007
e.) Basic Aspects of Tumour Immunology, Keystone Symposia, 2007
f.) Biological Markers and Surrogate Endpoints: Impact on Clinical Trials, DIA, 2007
g.) Research Regulations and Guidelines, HRCI Center for Clinical Research Education, 2007
h.) Technical Writing in the Pharmaceutical & Allied Industries, Center for Professional Advancement, 2007
i.) Feeding the Pipeline: Alternatives to the Late Stage Product Stampede, LES 2007
j.) Competitive Intelligence in Licensing Transactions, Licensing Executive Society, 2008
k.) Competitive Intelligence: Strategic Early Warning Concepts, SCIP, 2008
l.) Knowledge Management for Medical Affairs, Center for Business Intelligence, 2009
m.) Linking CI and Overall Competitive Advantage, Society for Competitive Intelligence Professional, 2009
4. Honours, Awards, Distinctions and Fellowships with dates
a.) Delta Mu Delta, National Business Administration Honour (2006 – Present)
b.) Technical Achievement Merit Awards, Takeda Pharmaceuticals, USA (June 2008 – Sept 2011)
c.) Technical Achievement Merit Awards, TAP Pharmaceuticals, Lake Forest, USA (May 1999 – May 2008)
d.) Patent Incentive Awards, NPS-Allelix Corporation, Mississauga, Canada (April 1993 – Dec 1998)
e.) Research Excellence in Molecular Biology, Wayne State University, Detroit, USA (Mar 1988 – Sept 1990)
f.) Canadian Commonwealth Fellowship Award, University of British Columbia, Canada (Aug 1982 - Aug 1987)
g.) Post-Graduate Scholarship, Federal Ministry of Education, Lagos, Nigeria (Aug 1981 – July 1982)
C. WORK EXPERIENCE OUTSIDE THE UNIVERSITY SYSTEM
1. Classroom Teacher, Ansar-Ur-Deen Primary School, Ile-Ife, Osun State (Aug 1973 – June 1974)
2. Integrated Science Teacher, Islamic Grammar School, Modakeke, Osun State
(Aug 1974 – June 1975)
3. National Youth Service Corps, Ningi High School, Ningi, Bauchi State (Aug 1980 –June 1981)
4. Biology Teacher, Origbo Community Grammar School, Ipetumodu, Osun State (Sept 1981-Jun 1982)
5. Molecular Biology Research Scientist, NPS-Allelix Corporation, Mississauga, Canada (Oct 1990 – May 1994)
6. Senior Research Scientist, Gene Structure & Function, NPS-Allelix, Schizophrenia Drug Discovery Research
Partnership with Sanofi-Aventis (Aug 1995 – Aug 1996)
7. Manager, Discovery Biology Department, NPS-Allelix: Gene cloning, Gene structure and Analysis, Cell
Biology, Gene Expression, and Biochemical Pharmacology (Sept 1996 – April 1999)
8. Senior Technical Assessment Scientist, Strategic R&D Planning & Operations, TAP Pharmaceutical Products
Inc., Lake Forest, IL U.S.A. (May 1999 – Sept 2001)
3
9. Assistant Director of Technical Assessment, Scientific Affairs, Research & Development Division, TAP
Pharmaceutical Products Inc., Lake Forest, IL. U.S.A. (Oct 2001 – June 2008)
10. Assistant Director, Medical & Scientific Intelligence, Takeda Pharmaceuticals North America, Inc., Deerfield,
IL. U.S.A. (June 2008 – June 2009)
11. Associate Director, Global Medical Affairs, Takeda Pharmaceuticals International, Inc., Deerfield, IL. U.S.A.
(June 2009 – Oct 2011)
D. WORK EXPERIENCE IN UNIVERSITIES, BIOTECHNOLOGY /PHARMACEUTICAL INDUSTRY
PARTNERSHIPS
1. Post-Graduate Research Assistant, Department of Microbiology & Immunology, The University of British
Columbia, Vancouver, BC Canada (Aug 1982 – July 1987)
2. Post-Graduate Teaching Assistant, Department of Microbiology & Immunology, The University of British
Columbia, Vancouver, BC Canada (Aug 1987 – Feb 1988)
3. Post-Doctoral Research Fellow, Department of Biochemistry, Wayne State University, School of Medicine,
Detroit, MI U.S.A. (Mar 1988 – Aug 1990)
4. Group Leader, NPS-Allelix in Research Partnership on Dopamine D4 Receptor with the University of
Toronto, Canada (June 1994 – July 1995)
5. Supervisor, NPS-Allelix in Co-operative Research Projects in Molecular Biology involving five
undergraduate students from the Universities of Guelph and Waterloo, Canada (Sept 1994 – Aug 1998)
6. Scientific Manager, NPS-Allelix in Research Collaborations on Neurotrophin and Serotonin Projects with The
Queen’s University, Department of Medicine, Canada and The University of Arizona Health Science Centre,
Texas, USA Corp (Sept 1996 – Dec 1998)
7. Visiting Senior Lecturer, Department of Medical Microbiology & Parasitology, College of Health Sciences,
Osun State University, Osogbo Nigeria (Oct 2011 – Aug 2012)
8. Coordinator, UniOsun Water Research Consortium, Osun State University (Dec 2011 – Aug 2012)
E. CO-CURRICULAR PROFESSIONAL EXPERIENCE
1. Member, Clinical Drug Candidate Selection Committee, NPS-Allelix Corp (1996-1997)
2. Scientific Liaison, New Business Group in discussions focused on R&D requirements (1999 – 2008)
3. Coordinator, Research and Development due diligence of drug product opportunities in Germany, Japan and
the United States of America (2000 – 2006)
4. Reviewer of scientific proposals and concepts on Prevacid life-cycle management initiatives (2001-2002)
5. Coordinator, Technical Assessment Standard Operating Procedures & Metrics (2002-2007)
6. Coordinator, Gastroenterology, Urology, Women’s Health Working Groups (2002, 2004)
7. Reviewer of scientific proposals, manuscripts and study protocols on leuprolide (Lupron) life-cycle
management, applications in immune system recovery, and low dose formulation for endometriosis (2006)
8. Coordinator, Technical writing, Non-clinical sections of two Investigational New Drug Applications and six
New Drug Applications on Lupron submitted to the United States Food & Drug Administration (2006 – 2008)
9. Scientific Lead, Technical Assessment & Due Diligence Committee (2007 – 2008)
10. Member, New Business Development & Strategic Planning Group (2001, 2004, 2007-2009)
4
11. Member, Biotechnology Symposium Committee, Department of Biological Sciences, Covenant
University, 2012 – present
12. Member, Curriculum Development Committee, Microbiology Unit, Department of Biological Sciences,
Covenant University, 2012 – present
13. Member, Appointments and Promotions Committee, Department of Biological Sciences, Covenant
University, 2013
14. Chairman, Department of Biological Sciences Journal Committee, Covenant University, 2013
15. Member, Editorial Advisory Board, Covenant Journal of Physical & Life Sciences, Covenant
University, 2013
F. MEMBERSHIP OF PROFESSIONAL BODIES
1.
2.
3.
4.
5.
6.
7.
8.
Chicago (Universities & Colleges) Assessment Group (2013)
Association of University Technology Managers (2011 - present)
Nigerian Association of Pharmacists and Pharmaceutical Scientists in the Americas, Inc. (2011
Licensing Executive Society (USA & Canada) (2007 – Present)
Society for Competitive Intelligence Professionals (2007 – Present)
Delta Mu Delta, National Business Administration Honour’s Society (2006 – Present)
American Society for Microbiology (1987 – 1991)
American Association for the Advancement of Science (1987-1991)
G. UNIVERSITY /COMMUNITY / NATIONAL/ INTERNATIONAL SERVICE
1. Invited Speaker on “Thinking of a Career in the Biotechnology/Pharmaceutical Industry”, University of
Waterloo, London, Ontario, Canada (1995-1997)
2. Coordinator, UniOsun Water Research Consortium, Osun State University, Osogbo (2011 –2012)
3. Reviewer for Strategic and Operating Grant Applications in the Renewable Bio-Energy Section, Natural
Sciences and Engineering Research Council, Canada (1992)
4. Reviewer for GENE: An International Journal on Genes and Genomes published in the U.S. (1997)
5. Chairman, Board of Elders, Faith Church Grayslake, IL, U.S.A. (2007-2008)
6. Vice-Chairman, Board of Elders, Faith Church Grayslake, IL, U.S.A. (2006-2007)
7. Member, Board of Elders, Heart Lake Baptist Church, Brampton, ON, Canada (1998-1999)
8. Member, Advisory Board, Making Services Work for People, Ministry of Community and Social Services,
ON, Canada (1994-1996)
9. Co-Leader, Covenant University Post-Graduate Biology Students’ Educational visit to International
Institute of Tropical Agriculture, Ibadan (2013)
H. COURSES TAUGHT / KNOWLEGDE TRANSMITTED
1. MCB 411: Environmental and Petroleum Microbiology, a final year undergraduate course dealing with the
composition of microbial communities, effects of pollution on microbial ecology, municipal waste management,
and the microbiology of water supply.
2. MCB 415: Pharmaceutical Microbiology and Antimicrobial Agents, a final undergraduate course dealing
with production of safe medicines and other healthcare products, free from undesired microbial contamination,
within clean and controlled environments.
5
3. MCB 413: Microbial Genetics, a final year undergraduate course dealing with the principles of bacterial
genetics, tools of genetic engineering, and applications of recombinant DNA in biotechnology.
4. MCB 315: Analytical Microbiology & Quality Control, a foundational course for third year undergraduate
students in microbiology on the principles of microbiological quality control and assurance as they pertain to
pharmaceutical and food industries.
5. MCB 822: Advanced Microbial Genetics, a graduate level course covering some aspects of microbial
genetics with major focus on the principles and techniques of recombinant DNA and their biotechnological
applications.
6. MCB 823: Advanced Environmental Microbiology, a graduate level course including a review of microbial
classification; and aspects of microbial metabolic diversity, microbial ecosystems, methods in microbial
ecology, nutrient cycles, and microbial bioremediation.
7. MCB 200, a foundational course for undergraduate students from the Departments of Microbiology &
Immunology, Medical Microbiology, Food Science & Technology, Biochemistry, Pharmacology, and
Biochemical Engineering
8. MCB 524, Advanced Techniques in Molecular Biology laboratory sessions for graduate students from the
Departments of Microbiology& Immunology, Biochemistry and Pharmacology
9. Regulatory Due Diligence comprising e-Learning Modules and hands-on workshop to more than 40
Pharmaceutical Research and Development professionals
10. Environmental Assessment impacting Cardio-metabolic, Gastroenterology and Internal Medicine
therapeutic areas to 25 post-doctoral Medical and Scientific Affairs professionals
11. Medical and Scientific Intelligence gathering, evaluating and regular reporting from coverage of National
and International Professional Meetings and Thought Leaders Feedback to 60 Clinical Sciences and Strategies
professionals (Pharmacists and Medical Doctors)
12. The scientific framework and medical education on Prevacid/NSAID Learning Modules for Takeda
Abbott Partnership’s Pharmaceutical Sales Force
13. Coordination of Seminar Presentations on Special Topics by external basic and clinical research faculty
and consultants
14. Development and administration of the Global Medical Affairs eXchange (MAx) intranet site integrating
medical and scientific knowledge in support of global medical strategies for Takeda Pharmaceuticals Company
I. RESEARCH STUDIES SUPERVISION
1. Supervision of 35 scientists and technicians (8 PhDs, 10 M.Sc. and 17 B.Sc. degree holders ) in Discovery
Biology research comprising gene cloning, gene structure and analysis, cell biology, gene expression and
biochemical pharmacology (1996 – 1999)
2. Supervision of five undergraduate honours’ and two post-graduate students research projects and seminars in
Molecular Biology topics (1989 - 1996)
3. Supervision of seven undergraduate students’ research projects on physico-chemical and bacteriological
assessment of drinking water in Osun State University Student Hostels near the main campus and Osogbo
metropolis (2011 – 2012)
4. Supervision of three undergraduate and one post-graduate (M.Sc.) students’ research projects, Covenant
University, Ota. 2012 - Present
6
J. PUBLICATIONS
(i) Theses / Dissertations
1. Owolabi, J. B. (1979) Isolation and characterization of aerobic bacteria from expired (human) blood samples
B.Sc. Thesis, University of Ife, Ile-Ife
2. Owolabi, J. B. (1982) Characterization of alkaline phosphatase from Agrobacterium tumefaciens C58
M.Sc. Thesis, University of Ife, Ile-Ife
3. Owolabi J. B. (1988). Characterization and expression of Cellulomonas fimi endoglucanase B gene and
properties of the gene product from Escherichia coli Ph.D. Thesis, University of British Columbia, Vancouver,
Canada
(ii) Articles in learned journals
1. Hendrix JA, Shimshock SJ, Shutske GM, Tomeer JD4th, Kapples KJ, Palermo MG, Corbett TJ, Vargas HM,
Kafka S, Brooks KM, Laws-Ricker L, Lee DK, de Lannoyl I, Bordeleau M, Rizkalla G, Owolabi J, Kamboj
RK. (2002). Synthesis and structure-activity relationship of the isoindolinyl benzisoxazolpiperidines as potent,
selective, and orally active human dopamine D4 receptor antagonists. Chembiochem 3(10): 999-1009. [Cited
by 4 articles]
2. Owolabi JB, Rizkalla G, Tehim A, Ross GM, Riopelle RJ, Kamboj R, Ossipov M, Bian D, Wegert S,
Porreca F, Lee DK. (1999). Characterization of the anti-allodynic action of ALE-0540 a novel nerve growth
factor receptor antagonist in the rat. J Pharmacol Exp Ther 289(3): 1271-6. [Cited by 89 articles]
3. Dou D, Owolabi JB, Dey S, Rosen BP. (1992). Construction of a chimeric ArsA-ArsB protein for
overexpression of the oxyanion-translocating ATPase. J Biol Chem. 267(36): 25768-75. [Cited by 11 articles]
4. Rosen BP, Hsu CM, Karkaria CE, Kaur P, Owolabi JB, Tisa LS. (1990). A plasmid-encoded aniontranslocating ATPase. Biochim Biophys Act. (BBA)-Bioenergetics 1018(2-3): 203-5. [Cited by 8 articles]
5. Owolabi JB, Rosen BP. (1990). Differential mRNA stability controls relative gene expression within the
plasmid-encoded arsenical resistance operon. J Bacteriol. 172(5):2367-71. [Cited by 62 articles]
6. San Francisco MJ, Hope CL, Owolabi JB, Tisa LS, Rosen BP. (1990). Identification of the metalloregulatory
element of the plasmid-encoded arsenical resistance operon. Nucleic Acids Res. 18(3):619-24. [Cited by 93
articles]
7. Rosen BP, Hsu CM, Karkaria CE, Owolabi JB, Tisa LS. (1990). Molecular analysis of an ATP-dependent
anion pump. Phil Trans R Soc Lond B Biol Sci. 326(1236):455-63. [Cited by 10 articles]
8. Owolabi JB, Beguin P, Kilburn DG, Miller RC, Warren RA. (1988). Expression in Escherichia coli of the
Cellulomonas fimi Structural Gene for Endoglucanase B. Appl Environ Microbiol. 54(2): 518-23. [Cited by 42
articles]
7
9. Warren RA, Gerhard B, Gilkes NR, Owolabi JB, Kilburn DG, Miller RC Jr. (1987). A bifunctional
exoglucanse-endoglucanase fusion protein. Gene 61(3): 421-7. [Cited by 29 articles]
(iii) Abstracts / Conference Proceedings / Symposia
1. Owolabi, Joshua B and Alebiosu, Christopher O. (2011). Self-Management of Type 2 Diabetes in Nigeria: A
Technical Assessment of Research Studies. Osun State University College of Health Sciences Faculty Research
Day, December 21.
2. Owolabi, Joshua B, Olaitan, Janet O, Oloke, Julius K, Olatunde, Ganiyu O. (2011). Ensuring Acceptable
Water Quality in Student Hostels and Other Premises Near the Main Campus of The Osun State University,
Osogbo, Nigeria. Osun State University College of Health Sciences Faculty Research Day, December 21.
3. McKnight G, Owolabi J, Penn J, Shah S. (2008). Bringing competitive intelligence to the top: Delivering
intelligence to executives. Pharma CI Conference & Exhibition, Iselin, New Jersey, USA
4. Fantaske RP, Jarvie KR, Sharma S, Wong L, Kamboj R, Owolabi JB. (1998). Dopamine D4 receptor
mutagenesis: role of aspartate 80 in regulation of function, agonist and antagonist binding. Society for
Neuroscience, Vol 24, 28th Annual Meeting.
5. Sharma S, Fantaske RP, Kell MS, Owolabi JB, Jarvie KR, Kamboj RK, Lee DK. (1997). Generation and
characterization of antibodies specific for human dopamine D4 receptor. Poster 271.2 Society for Neuroscience,
Vol 23 Part 1, page 263. 27th Annual Meeting.
6. Kirby RA, Rakhit S, Owolabi J, Kamboj RK. (1994). A molecular modeling study of dopamine in the D2
and D4 receptors. 8th International Symposium on Molecular Recognition and Inclusion.
7. Owolabi J, Martin A, Rampersad V, Hoo K, Kamboj RK. (1994). Construction and characterization of stable
mammalian cell lines expressing human D4 dopamine receptors. XIIth International Congress of Pharmacology.
8. Dou D, Dey S, Owolabi JB, Rosen BP. (1992). Overexpression of the membrane component of an oxyaniontranslocating ATPase and ATP-driven anion transport into everted membrane vesicles in Escherichia coli. In:
Scarpa A, Carafoli E, Papa S (eds) The New York Academy of Sciences Conference on Ion-Motive ATPases:
Structure, Function and Regulation. Clevaland, Ohio, Abstract PIII.
9. De Grandis SA, Sibley S, Owolabi J, Zhang Y, Bozzato R.(1992). Nucleic acid sequence similarities of the
estrogen receptor gene in breast tumor and osteosarcoma cells. J. Cell Biochem Suppl. 16C: 15. Keystone
Symposia on Molecular and Cellular Biology.
10. Rosen BP, Hsu CM, Hope CL, Karkaria CE, Owolabi JB, Kaur P, Tisa LS, Wu JH. (1989).
Characterization of a bacterial oxyanion translocating ATPase. Membrane Physiology in Microorganisms: From
Membrane to Gene.
8
11. Arfman N, Gilkes NR, Guo Z, Kilburn DG, Langsford M, Owolabi J, Miller RC Jr, Warren RA. (1987).
Characterization of Cellulomonas fimi cellulases. Grander C. (ed) Sixth Canadian Bioenergy Research and
Development, Elsevier, New York, NY, pp 290-292.
12. Gilkes NR, Kilburn DG, Langsford M, Miller RC Jr, O’Neil GP, Owolabi JB, Wakarchuk W, Warren RA,
Whittle DJ, Wong WKR. (1984). The cloning of Cellulomonas fimi cellulase genes in Escherichia coli. In:
Hasnain S (ed) Fifth Canadian Bioenergy Research and Development, Elsevier, New York, NY, pp. 582.
(iv) Technical Scientific Assessment Reports (Confidential papers that informed corporate executives’
strategic management decisions)
1. Owolabi, J. (1996) Pharmacological characterization of 5-thienytryptamine derivatives and benzylimidazolines as 5-HT1b/1d agonists with potential in the treatment of migraine and selection of ALX-0646 as a
clinical drug development candidate
2. Owolabi, J. (1996) Pharmacological characterization of 5-HT 2C ligands (quinoline derivatives) using 5-HT
2a, 2b and 2c mammalian cell-based test systems
3. Owolabi, J. (1996) Pharmacological characterization of 5-HT6 ligands (2-substituted tryptamines) using 5HT6 mammalian cell-based test systems
4. Owolabi J. (1999) Scientific assessment of ALX1-11, recombinant human parathyroid hormone, rhPTH-1-84,
in clinical development for the treatment of osteoporosis in men and women
5. Owolabi J. (1999) Evaluation and regulatory due diligence of R-Terazosin, a selective adrenergic alpha 1
antagonist, for clinical development in the treatment of men with benign prostatic hyperplasia
6. Owolabi, J. (2000) Technical assessment of FR229934, a phospho-diesterase IV inhibitor, for clinical
development in the treatment of male erectile dysfunction
7. Owolabi J. (2001) Technical assessment and regulatory due diligence of Symlin, an analogue of insulinoma
amyloid polypeptide (IAPP or amylin), in clinical development in the treatment of diabetes
8. Owolabi J. (2001) Technical assessment and regulatory due diligence of Cilansetron, a serotonin receptor 3
antagonist, in clinical development for the treatment of women with diarrhea-predominant irritable bowel
disease syndrome
9. Owolabi J. (2002) Selection of Naproxen as an NSAID in the development of Prevacid/NSAID combination
pack program
10. Owolabi J. (2002) Evaluation of Visicol as a co-promotion product in the U.S. colon cleansing market.
11. Owolabi J. (2003) Technical assessment and regulatory due diligence of ABT-224, a serotonin 4 receptor
agonist, in clinical development for the treatment of chronic constipation and constipation-predominant irritable
bowel syndrome
9
12. Owolabi J. (2004) Provenge: Immunotherapy in late stage development for the treatment of prostate cancer
13. Owolabi J. (2005) Evaluation of non-surgical and endoscopic treatment solutions for Barrett's esophagus
14. Owolabi J. (2005) Assessment of ospemifene and fispemifene for clinical development in the treatment of
vaginal atrophy, and prevention and treatment of osteoporosis in postmenopausal women
15. Owolabi J. (2006) Evaluation of Darifencacin, an anti-cholinergic investigational drug, for the treatment of
overactive bladder symptoms
16. Owolabi J. (2006) Assessment of the Tice strain of Bacillus Calmette-Guérin Immunotherapy for the
treatment of superficial bladder cancer
17. Owolabi J. (2006) Technical assessment of Cetrorelix, a gonadotrophin-releasing hormone (GnRH)
antagonist, in clinical development for the treatment of benign prostatic hyperplasia
18. Owolabi, J. (2006) Non-clinical pharmacology section of an Investigator’s Brochure IND on Leuprolide
(Lupron) for enhanced immune system recovery
19. Owolabi J. (2007) Evaluation of Fesoteridine, an anti-cholinergic investigational agent, for clinical
development in the treatment of over-active bladder symptoms
20. Owolabi J. (2008) Technical assessment and regulatory due diligence of GVAX, an immunotherapeutic, in
late-stage clinical development for the treatment of prostate cancer
(v) Patents and Inventions
Patents Granted:
1. Owolabi J, Rampersad V, Kamboj J. (1998) U.S. Patent No.5, 846, 823.
2. Owolabi J, Rampersad V, Kamboj R. (1997) EP Patent 0,804,569.
3. Owolabi J, Rampersad V, Kamboj J. (1995) WO Patent WO/1995/009,237 (International Application No.:
PCT/CA1994/000,538) Expression of human D4 dopamine receptors in stable cell lines.
Technical Contributions (subjects of corporate know-hows and trade secrets):
1. Bicyclic Piperidine and Piperazine Compounds Having 5-HT6 Receptor Affinity
2. 5-Bicycloinidole Compounds
3. Benzylated Clozapine Analogs
4. Dimethylated Clozapine Analogs
5. Benzamides having Dopamine D4 Receptor Affinity
6. Bicyclic Nonane & Docane Compounds having Dopamine Receptor Affinity
7. Muscarinic Receptor Ligands
8. Troponyl Piperazines as Dopamine D4 Receptor Ligands
10
1998
1998
1997
1997
1997
1997
1996
1996
K. CURRENT RESEARCH ACTIVITIES
(i)
Funded Research: None
(ii)
Non-funded / self-sponsored Research:
a) Physico-chemical and bacteriological assessment of packaged “pure water”, borehole and well
groundwater sources.
b) Microbiological quality of fresh and smoked fish, and ready-to-eat vegetables from Ota food
markets
c) Antibacterial tests on the effectiveness of hand sanitizers.
d) Evaluation of Nigerian medicinal plants for anti-microbial and other therapeutic activities.
e) Molecular mechanisms of heavy metal toxicity
L. SELECTED CONFERENCES ATTENDED
1.
Society for Neuroscience, 28th Annual Meeting, Washington, DC, USA, 1997
2. Endocrinology Society Annual Conference, 2000
3. Pharmaceutical CI Conference & Exhibition, Iselin, New Jersey, USA, 2007
4. Keystone Symposia on Tumor Immunology, 2007
5. Drugs Information Association Annual Conference, 2006, 2007
6. Licensing Executives Society Annual Conference, 2002, 2007
7. Society for Competitive Intelligence Professionals Annual Conference, 2008, 2009
M. EXTRA CURRICULUM ACTIVITIES
1. Reading
2. Journaling
3. Counseling
4. Football/Soccer
5. Walking
N. OTHER KEY ACCOMPLISHMENTS
1. Accelerated drug discovery by managing the development of 14 G-protein coupled receptor cell-based
compound screening reagents
2. Discovered small molecule nerve growth factor antagonists, 1st in series of new pain killer class to enter the
multibillion chronic pain market
3. Discovered novel chemical entities with potential in treating patients with obesity and schizophrenia by
managing team research involved in pharmacological assessments of 5-thienytryptamine derivatives,
benzylimidazolines, and quinoline derivatives in serotonin receptor cell-based assay systems
4. Instrumental in fostering and sustaining strategic partnerships with two of top 10 global pharmaceutical
companies through development of screening reagents that led to discovery and characterization of therapeutics
and research milestone payments of more than $5 million over 3 years
5. Orchestrated pre-clinical to phase I clinical drug development for pain programs which became major assets
in strategic out-licensing to major U.S. pharmaceutical company
11
6. Directed teams of 12 technical, scientific, and business staff in 3 strategic industry sponsored research
collaborations with the University of Toronto, Queen’s University, and University of Arizona Health Science
Center
7. Contributed to continued United States Federal Drug Administration’s annual marketing approval of $800
million branded oncology/urology product through coordination of technical writing of non-clinical sections of
2 Investigational New Drug Applications and 6 New Drug Applications
8. Enhanced the quality of clinical and commercial strategic plans by advocating and establishing Technical
Competitive Intelligence functions for Medical and Scientific Affairs departments in 3 subsidiaries of Takeda
Pharmaceutical Company
9. Ensured successful corporate restructuring by managing transition and alignment of activities of 50-member
Molecular Biology Research and Development department
10. Managed cross-functional teams on the due diligence of more than 20 product opportunities with innovation
partners in Asia, Europe and North America
11. Achieved executive in-licensing consideration of 10 small molecules and biologics, in early to late stage
development, focused on gastroenterology, metabolic diseases, urology and oncology markets
12. Advanced line extension of franchise with annualized revenue increase of $50 million through assessment of
proton pump inhibitor and non-steroidal anti-inflammatory drug combination pack
13. Conducted scientific evaluation of more than 500 drug research proposals, discovery targets, compound
leads and biologics focused on oncology, gastroenterology, metabolic diseases, urology, women’s health, mental
disorders, anti-microbial infection and inflammation markets
12